A. ARDRON LIMITED

Company number 04872697 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: A. ARDRON LIMITED

1. Financial Health Score: B

Grade Explanation: The company exhibits a fundamentally sound balance sheet with excellent liquidity and minimal debt—similar to a patient with a strong constitution. However, there are chronic symptoms of declining retained earnings and a significant shift in asset composition that warrant monitoring. The company is not in acute distress, but the steady erosion of equity over recent years suggests an underlying condition that requires attention.


2. Key Vital Signs

Vital Sign Reading (2025) Previous Year (2024) Trend Interpretation
Net Assets £212,346 £225,149 ▼ Declining Consistent erosion of wealth – down 5.7% year-on-year
Cash Position £106,550 £209,375 ▼▼ Significant decline Cash halved – a dramatic drop of 49%
Investments £109,619 £25,500 ▲▲ Significant increase Portfolio expanded by 330%
Current Liabilities £5,214 £10,795 ▲ Improving Liabilities nearly halved – healthy reduction
Current Ratio 41.5:1 21.8:1 ▲ Improving Exceptional ability to meet short-term obligations
Debt-to-Equity 2.6% 4.8% ▲ Improving Virtually no leverage – no debt dependency
Retained Earnings £212,246 £225,049 ▼ Declining Decreased by £12,803 – indicates loss or dividend extraction

10-Year Net Assets Trajectory

£260K ┤ ╭───╮ £250K ┤ ╭──╮ │ │ £240K ┤╭──╮ │ ╰──────╯ ╰───────────── £230K ┤╯ ╰───╯ ╰── ? £220K ┤ ╰── £210K ┤ ╰── £212K └──┬───┬───┬───┬───┬───┬───┬───┬───┬───┬──┘ 2016 17 18 19 20 21 22 23 24 2025


3. Diagnosis

What the Financial Data Reveals About Business Health

The Patient: A Mature Investment Vehicle

A. ARDRON LIMITED, incorporated in 2003, operates as a micro-company within the "other business support service activities" sector with a single employee (the director). The financial anatomy reveals a business that functions primarily as an investment holding vehicle rather than a trading enterprise.

Primary Symptoms

Symptom 1: Chronic Retained Earnings Erosion Over the past three years, retained earnings have declined consistently: - 2022→2023: Decrease of £22,714 - 2023→2024: Decrease of £10,421 - 2024→2025: Decrease of £12,803

This pattern is like a patient losing weight steadily over several years—it may not be immediately dangerous, but the underlying cause must be identified. The erosion suggests either operating losses, dividend extraction by the 100% shareholder, or a combination of both.

Symptom 2: Dramatic Asset Composition Shift The most striking vital sign change is the transformation of the balance sheet composition:

Asset Type 2024 2025 Change
Cash £209,375 £106,550 -£102,825 (-49%)
Investments £25,500 £109,619 +£84,119 (+330%)

The company has effectively transferred approximately £103,000 from cash into listed investments. This is akin to a patient converting savings into a more volatile asset class—potential for higher returns, but also greater risk of capital loss.

Symptom 3: Minimal Trading Activity The extremely low creditor balances (VAT: £764, other creditors: £650) and single employee suggest minimal revenue-generating operations. The business appears to derive value primarily from investment returns and asset management rather than active trading.

Secondary Symptoms

Positive Indicators: - Robust Liquidity: With a current ratio of 41.5:1, the company can meet its obligations 41 times over—exceptionally healthy - Minimal Debt: Only £5,214 in current liabilities with no long-term debt - Compliance Health: Accounts filed on time, no overdue filings, active status maintained for 22 years

Concerning Indicators: - No Visible Revenue Stream: The absence of turnover data in filleted accounts and minimal creditor activity suggests limited trading income - Investment Concentration Risk: £109,619 in listed investments represents 51% of total assets—significant exposure to market volatility - Cash Runway Concern: If cash continues declining at this rate without replenishment, liquidity could become constrained within 2-3 years

Overall Clinical Picture

The company resembles a financially stable individual living off accumulated wealth rather than earned income. The "body" is fundamentally healthy—no debt dependency, strong asset base, excellent liquidity—but there are signs of a slow, steady drawdown of reserves. The recent shift from cash to investments introduces market risk that wasn't previously a significant factor.


4. Prognosis

Future Financial Outlook

Short-term (1-2 years): STABLE WITH MONITORING REQUIRED

The company has sufficient resources to continue operating indefinitely at current expenditure levels. However, the trajectory depends heavily on: 1. Investment performance on the £109,619 listed portfolio 2. Whether dividend extraction continues at recent rates 3. Whether any revenue-generating activities are developed

Medium-term (3-5 years): CONDITION MAY WORSEN IF UNADDRESSED

If retained earnings continue declining at the recent average of approximately £15,000 per year, net assets could fall below £170,000 by 2030. While not immediately threatening, this represents a 20% further decline in the company's wealth base.

Key Risk Factors: - Market Volatility: The significant investment portfolio exposes the company to stock market fluctuations - Income Dependency: Without visible trading revenue, the company relies on investment returns and existing capital - Concentrated Control: 100% ownership by one individual creates key-person dependency


5. Recommendations

Prescribed Course of Treatment

Immediate Actions (0-6 months):

  1. Investment Portfolio Health Check - Review the composition and risk profile of the £109,619 listed investment portfolio - Ensure appropriate diversification to protect against market downturns - Consider whether the risk appetite matches the company's declining equity trajectory

  2. Cash Flow Forecasting - Project cash requirements for the next 12-24 months - Determine minimum cash reserves needed for operational expenses and tax obligations - Establish a threshold below which cash should not fall (e.g., £50,000)

Medium-term Actions (6-18 months):

  1. Revenue Generation Assessment - Evaluate whether the business support services SIC code (82990) represents active trading or dormant capability - Consider developing revenue-generating activities to offset the retained earnings erosion - Explore whether the company's skills and resources can generate consulting or service income

  2. Dividend Policy Review - If the retained earnings decline is primarily due to dividend extraction, model sustainable withdrawal rates - Consider retaining more earnings to preserve the capital base - Balance shareholder income needs with long-term company health

Long-term Strategic Considerations:

  1. Business Model Evaluation - Assess whether the current structure as an operating company remains appropriate, or whether the business has effectively become an investment holding vehicle - Consider whether alternative structures might be more tax-efficient for the shareholder

  2. Succession Planning - Given the single-director structure, ensure appropriate contingency plans exist for business continuity


Monitoring Schedule

Metric Current Watch Threshold Alert Threshold
Net Assets £212,346 Below £200,000 Below £180,000
Cash Position £106,550 Below £80,000 Below £50,000
Current Ratio 41.5:1 Below 20:1 Below 10:1
Investment % of Assets 51% Above 65% Above 75%
Annual Retained Earnings Change -£12,803 Below -£15,000 Below -£25,000

Perspective: Financial Health Diagnostician · Model: glm-5.1 · Generated 12 August 2026